Table 2. Effect of BIO 5192 on... | American Society of Hematology

Table 2.

Effect of BIO 5192 on relapsing-remitting EAE when administered for 22 or 44 days beginning at the peak of acute EAE

	On-drug treatment					Off-drug treatment
Treatment/duration^*	Mean peak clinical score	Severity index	Relapse rate	Mean peak clinical score	Severity index^*	Relapse rate
Vehicle/22 Rx	2.09 ± 0.12	0.60 ± 0.14	0.39	1.08 ± 0.23	0.81 ± 0.24	0.42
BIO 5192/22 Rx	1.96 ± 0.13	0.29 ± 0.10^*	0.17^*	2.64 ± 0.28^*	1.77 ± 0.20^*	1.00^*
Vehicle/44 Rx	2.00 ± 0.07	0.66 ± 0.13	1.05	1.30 ± 0.15	0.82 ± 0.15	0.30
BIO 5192/44 Rx	2.00 ± 0.12	0.43 ± 0.13	0.52^*	2.44 ± 0.34^*	1.80 ± 0.23^*	1.00^*

	On-drug treatment					Off-drug treatment
Treatment/duration^*	Mean peak clinical score	Severity index	Relapse rate	Mean peak clinical score	Severity index^*	Relapse rate
Vehicle/22 Rx	2.09 ± 0.12	0.60 ± 0.14	0.39	1.08 ± 0.23	0.81 ± 0.24	0.42
BIO 5192/22 Rx	1.96 ± 0.13	0.29 ± 0.10^*	0.17^*	2.64 ± 0.28^*	1.77 ± 0.20^*	1.00^*
Vehicle/44 Rx	2.00 ± 0.07	0.66 ± 0.13	1.05	1.30 ± 0.15	0.82 ± 0.15	0.30
BIO 5192/44 Rx	2.00 ± 0.12	0.43 ± 0.13	0.52^*	2.44 ± 0.34^*	1.80 ± 0.23^*	1.00^*

Data shown are ± SEM. ^*Off-treatment severity index was calculated for 20 days beginning 4 days following cessation of the 22-day treatment regimen and for 12 days beginning 4 days following cessation of the 44-day treatment regimen.

†P < .05 vs vehicle-treated control value.

View Large

This Feature Is Available To Subscribers Only